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Open acHBeAg-positive chronic hepatitis B patients with prior
long-time exposure to nucleos(t)ide analogues: ‘‘Switch-to’’
or ‘‘add-on’’ PegIFN alfa, that is the questionpractice. Obviously, large clinical trials are needed to further
clarify the above hypothesis and its underlying mechanism.
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We read with great interest the paper by Ning et al. [1] about the
efﬁcacy of switching from entecavir to PegIFN alfa-2a in patients
with HBeAg-positive chronic hepatitis B (CHB). In this
prospective study, hepatitis B e antigen-positive CHB patients
who had received entecavir for 9–36 months were randomized
1:1 to switch to PegIFN alfa-2a or to continue with entecavir
for 48 weeks. It showed that only 14.9% patients achieved HBeAg
seroconversion and 8.5% patients achieved HBsAg loss in the Peg-
IFN alfa-2a cohort at week 48. The authors indicated that HBeAg
loss and seroconversion were less likely to occur in patients with
prior long-time exposure to a nucleos(t)ide analogue (NUC) com-
pared with treatment-naïve patients. However, ‘‘add-on’’ PegIFN
alfa to a current NUC therapy has been shown to lead to a high
rate of HBsAg loss in some small cohort studies [2,3]. Moreover,
the complete response (HBeAg loss and HBV DNA <2000 IU/ml)
and HBsAg loss rates were much higher in patients with sequen-
tial combination therapy in our recent retrospective study. In the
sequential combination therapy cohort, PegIFN alfa-2a was added
to HBeAg-positive CHB patients who had received NUC for at
least two years. It showed that complete response and HBsAg loss
rates in the ‘‘add-on’’ PegIFN alfa-2a cohort were 60.2% and 27.7%
at week 72 (48 week treatment and 24 week follow-up), respec-
tively [4]. Since the study design and inclusion criteria are differ-
ent, we can hardly draw the conclusion that sequential
combination therapy with PegIFN alfa (‘‘add-on’’) is better than
‘‘switch-to’’ PegIFN alfa in patients with prior long-time exposure
to NUC.
Nevertheless, some recent studies have further found that
PegIFN alfa therapy may beneﬁt more from the combination ther-
apy with NUC. First, PegIFN alfa therapy induced the expansion of
natural killer (NK) cell populations, which was detrimental to
CD8 T cells [5,6] and conversely, NUC playing a role in the resto-
ration of adaptive antiviral responses had already been proven in
an earlier study [7]. Thus, it was suggested that the combination
with NUC addresses the limitation of the PegIFN alfa therapy.
Second, chronic HBV patients became refractory to multiple
doses of PegIFN alfa, which could be reduced by the combination
of PegIFN alfa and tenofovir [8]. Third, the combination therapy
might avoid the replenishment of nuclear cccDNA after degrada-
tion [9]. Although early and recent clinical trials showed no extra
beneﬁt of simultaneous combination therapy compared to Peg-
IFN alfa monotherapy, more evidence had shown that sequential
combination therapy with late ‘‘add-on’’ PegIFN alfa to an ongo-
ing NUC treatment instead of simultaneous combination therapy
might be more beneﬁcial [10]. With increasing data ﬁnding an
extra beneﬁt of combination therapy, we suggest that
‘‘add-on’’ may be more suitable than ‘‘switch-to’’ PegIFN alfa
therapy for patients with prior exposure to NUC in clinicalJournal of Hepatology 2015 vol. 62 j 238–251 239
cess under CC BY-NC-ND license.
